Evidence map›Paper›PMID 39102117›Full record

ArticleJournal of neuro-oncology2024

Establishing the utility of multi-platform liquid biopsy by integrating the CSF methylome and proteome in CNS tumours.

A P Landry, J A Zuccato, V Patil, M R Voisin, J Z Wang, Y Ellenbogen, C Gui, A Ajisebutu, T Kislinger, F Nassiri and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

A P LandryMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.
J A ZuccatoMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.
V PatilMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.
M R VoisinMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.
J Z WangMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.
Y EllenbogenMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.
C GuiMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.
A AjisebutuMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.
T KislingerDepartment of Medical Biophysics, University of Toronto, Toronto, Canada.
F NassiriMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. farshad.nassiri@mail.utoronto.ca.
G ZadehMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. gelareh.zadeh@uhn.ca.

Funding

Establishing the clinical utility of cell-free tumor DNA methylation profiling as a reliable liquid biopsy approach in brain tumorsR01CA263196 · NCI · UNIVERSITY HEALTH NETWORK · PI Daniel De Carvalho, Gelareh Zadeh · 2022 to 2026
$1.9M
NCI NIH HHS R01 CA263196
6 · The paper itself

Abstract

backgroundLiquid biopsy represents a major development in cancer research, with significant translational potential. Similarly, it is increasingly recognized that multi-omic molecular approaches are a powerful avenue through which to understand complex and heterogeneous disease biology. We hypothesize that merging these two promising frontiers of cancer research will improve the discriminatory capacity of current models and allow for improved clinical utility.

methodsWe have compiled a cohort of patients with glioblastoma, brain metastasis, and primary central nervous system lymphoma. Cell-free methylated DNA immunoprecipitation (cfMeDIP) and shotgun proteomic profiling was obtained from the cerebrospinal fluid (CSF) of each patient and used to build tumour-specific classifiers.

resultsWe show that the DNA methylation and protein profiles of cerebrospinal fluid can be integrated to fully discriminate lymphoma from its diagnostic counterparts with perfect AUC of 1 (95% confidence interval 1-1) and 100% specificity, significantly outperforming single-platform classifiers.

conclusionsWe present the most specific and accurate CNS lymphoma classifier to date and demonstrates the synergistic capability of multi-platform liquid biopsies. This has far-reaching translational utility for patients with newly diagnosed intra-axial brain tumours.

Indexed as

Biomarkers, TumorCentral Nervous System NeoplasmsDNA MethylationProteomeAdultAgedBrain NeoplasmsEpigenomeFemaleGlioblastomaHumansLiquid BiopsyLymphomaMaleMiddle AgedProteomicsBiomarkers, TumorProteomeBrain metastasesClassifierGlioblastomaLiquid biopsyLymphomaMethylationMulti-platformProteomics

Identifiers

PMID39102117
PMCPMC11915530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.